{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T07:18:32Z","timestamp":1788247112115,"version":"build-2803163510"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Metab Health Dis"],"DOI":"10.1038\/s44324-026-00131-3","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T07:10:38Z","timestamp":1788246638000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Higher semaglutide dose is associated with lower neuropsychiatric event incidence independent of weight loss"],"prefix":"10.1038","volume":"4","author":[{"given":"Karthik","family":"Murugadoss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. J.","family":"Venkatakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venky","family":"Soundararajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"131_CR1","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding, J. P. H. et al. Once-weekly semaglutide in adults with overweight or obesity. N. Engl. J. Med. 384, 989\u20131002 (2021).","journal-title":"N. Engl. J. Med."},{"key":"131_CR2","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff, A. M. et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N. Engl. J. Med. 389, 2221\u20132232 (2023).","journal-title":"N. Engl. J. Med."},{"key":"131_CR3","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic, V. et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N. Engl. J. Med. 391, 109\u2013121 (2024).","journal-title":"N. Engl. J. Med."},{"key":"131_CR4","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","volume":"390","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod, M. N. et al. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N. Engl. J. Med. 390, 1394\u20131407 (2024).","journal-title":"N. Engl. J. Med."},{"key":"131_CR5","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff, A. M. et al. Tirzepatide once weekly for the treatment of obesity. N. Engl. J. Med. 387, 205\u2013216 (2022).","journal-title":"N. Engl. J. Med."},{"key":"131_CR6","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1056\/NEJMoa2416394","volume":"393","author":"LJ Aronne","year":"2025","unstructured":"Aronne, L. J. et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N. Engl. J. Med. 393, 26\u201336 (2025).","journal-title":"N. Engl. J. Med."},{"key":"131_CR7","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","volume":"391","author":"A Malhotra","year":"2024","unstructured":"Malhotra, A. et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N. Engl. J. Med. 391, 1193\u20131205 (2024).","journal-title":"N. Engl. J. Med."},{"key":"131_CR8","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","volume":"392","author":"M Packer","year":"2025","unstructured":"Packer, M. et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N. Engl. J. Med. 392, 427\u2013437 (2025).","journal-title":"N. Engl. J. Med."},{"key":"131_CR9","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","volume":"391","author":"R Loomba","year":"2024","unstructured":"Loomba, R. et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N. Engl. J. Med. 391, 299\u2013310 (2024).","journal-title":"N. Engl. J. Med."},{"key":"131_CR10","doi-asserted-by":"publisher","first-page":"4186","DOI":"10.2337\/db14-0849","volume":"63","author":"L van Bloemendaal","year":"2014","unstructured":"van Bloemendaal, L. et al. GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans. Diabetes 63, 4186\u20134196 (2014).","journal-title":"Diabetes"},{"key":"131_CR11","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1111\/dom.12506","volume":"17","author":"L van Bloemendaal","year":"2015","unstructured":"van Bloemendaal, L. et al. Brain reward-system activation in response to anticipation and consumption of palatable food is altered by glucagon-like peptide-1 receptor activation in humans. Diab. Obes. Metab. 17, 878\u2013886 (2015).","journal-title":"Diab. Obes. Metab."},{"key":"131_CR12","unstructured":"GTEx Consortium. The GTEx Consortium atlas of genetic regulatory effects across human tissues. Science 369, 1318\u20131330 (2020)."},{"key":"131_CR13","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/s41586-024-08504-8","volume":"639","author":"JA Tadross","year":"2025","unstructured":"Tadross, J. A. et al. A comprehensive spatio-cellular map of the human hypothalamus. Nature 639, 708\u2013716 (2025).","journal-title":"Nature"},{"key":"131_CR14","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.2337\/dbi21-0003","volume":"70","author":"MQ Ludwig","year":"2021","unstructured":"Ludwig, M. Q., Todorov, P. V., Egerod, K. L., Olson, D. P. & Pers, T. H. Single-cell mapping of GLP-1 and GIP receptor expression in the dorsal vagal complex. Diabetes 70, 1945\u20131955 (2021).","journal-title":"Diabetes"},{"key":"131_CR15","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41586-024-07685-6","volume":"632","author":"K-P Huang","year":"2024","unstructured":"Huang, K.-P. et al. Dissociable hindbrain GLP1R circuits for satiety and aversion. Nature 632, 585\u2013593 (2024).","journal-title":"Nature"},{"key":"131_CR16","doi-asserted-by":"publisher","DOI":"10.1126\/science.adt0773","volume":"387","author":"Z Zhu","year":"2025","unstructured":"Zhu, Z. et al. Hedonic eating is controlled by dopamine neurons that oppose GLP-1R satiety. Science 387, eadt0773 (2025).","journal-title":"Science"},{"key":"131_CR17","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/s42003-021-02208-9","volume":"4","author":"Z Li","year":"2021","unstructured":"Li, Z. et al. Systemic GLP-1R agonist treatment reverses mouse glial and neurovascular cell transcriptomic aging signatures in a genome-wide manner. Commun. Biol. 4, 656 (2021).","journal-title":"Commun. Biol."},{"key":"131_CR18","doi-asserted-by":"crossref","unstructured":"Venkatakrishnan, A. J., Murugadoss, K. & Soundararajan, V. Weight loss dynamics and health burden changes with tirzepatide versus semaglutide. PNAS Nexus 5, pgag171 (2026).","DOI":"10.1093\/pnasnexus\/pgag171"},{"key":"131_CR19","doi-asserted-by":"crossref","unstructured":"Murugadoss, K., Varma, G., Venkatakrishnan, A. J., Gibson, M. C. & Soundararajan, V. Weight trajectories after last tirzepatide or semaglutide prescription across a federated health network. Biol. methods protoc. 11, bpag020 (2026).","DOI":"10.1093\/biomethods\/bpag020"},{"key":"131_CR20","doi-asserted-by":"publisher","unstructured":"Venkatakrishnan, A. J. et al. Clinical nSights: a software platform to accelerate real world oncology analyses. J. Clin. Oncol. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.e23316 (2024).","DOI":"10.1200\/JCO.2024.42.16_suppl.e23316"},{"key":"131_CR21","doi-asserted-by":"publisher","first-page":"D886","DOI":"10.1093\/nar\/gkae1142","volume":"53","author":"CZI Cell Science Program","year":"2025","unstructured":"Cell Science Program, C. Z. I. et al. CZ CELLxGENE Discover: a single-cell data platform for scalable exploration, analysis and modeling of aggregated data. Nucleic Acids Res. 53, D886\u2013D900 (2025).","journal-title":"Nucleic Acids Res."},{"key":"131_CR22","doi-asserted-by":"publisher","first-page":"gag171","DOI":"10.1093\/pnasnexus\/pgag171","volume":"5","author":"AJ Venkatakrishnan","year":"2026","unstructured":"Venkatakrishnan, A. J., Murugadoss, K. & Soundararajan, V. Weight-loss dynamics with tirzepatide versus semaglutide. PNAS Nexus 5, gag171 (2026).","journal-title":"PNAS Nexus"},{"key":"131_CR23","doi-asserted-by":"publisher","DOI":"10.1093\/biomethods\/bpag035","volume":"11","author":"G Varma","year":"2026","unstructured":"Varma, G. et al. Auditable large language model curation of clinical notes refines glucagon-like peptide-1 initiation, persistence ascertainment, and compounding use beyond prescription records. Biol. Methods Protoc. 11, bpag035 (2026).","journal-title":"Biol. Methods Protoc."},{"key":"131_CR24","doi-asserted-by":"crossref","unstructured":"Matson, R., Murugadoss, K., Venkatakrishnan A. J. & Soundararajan V. Semaglutide and Tirzepatide in Type 1 Diabetes: Real-World Insulin Deintensification, Cardiovascular Outcomes and Safety Assessment. https:\/\/www.preprints.org\/manuscript\/202606.0638 (2026).","DOI":"10.20944\/preprints202606.0638.v1"},{"key":"131_CR25","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.neubiorev.2016.11.017","volume":"72","author":"N Veronese","year":"2017","unstructured":"Veronese, N. et al. Weight loss is associated with improvements in cognitive function among overweight and obese people: a systematic review and meta-analysis. Neurosci. Biobehav. Rev. 72, 87\u201394 (2017).","journal-title":"Neurosci. Biobehav. Rev."},{"key":"131_CR26","doi-asserted-by":"publisher","unstructured":"Cummings, J. L. et al. Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer\u2019s disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials. Lancet https:\/\/doi.org\/10.1016\/S0140-6736(26)00459-9 (2006).","DOI":"10.1016\/S0140-6736(26)00459-9"},{"key":"131_CR27","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S2215-0366(26)00014-3","volume":"13","author":"H Taipale","year":"2026","unstructured":"Taipale, H. et al. Association between GLP-1 receptor agonist use and worsening mental illness in people with depression and anxiety in Sweden: a national cohort study. Lancet Psychiatry 13, 327\u2013335 (2026).","journal-title":"Lancet Psychiatry"},{"key":"131_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-75965-2","volume":"14","author":"E Kornelius","year":"2024","unstructured":"Kornelius, E., Huang, J.-Y., Lo, S.-C., Huang, C.-N. & Yang, Y.-S. The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon like peptide-1 receptor agonist therapy. Sci. Rep. 14, 24433 (2024).","journal-title":"Sci. Rep."},{"key":"131_CR29","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1038\/ijo.2011.2","volume":"35","author":"AN Fabricatore","year":"2011","unstructured":"Fabricatore, A. N. et al. Intentional weight loss and changes in symptoms of depression: a systematic review and meta-analysis. Int. J. Obes. 35, 1363\u20131376 (2011).","journal-title":"Int. J. Obes."},{"key":"131_CR30","doi-asserted-by":"crossref","unstructured":"Chen, Z. et al. GLP-1R-positive neurons in the lateral septum mediate the anorectic and weight-lowering effects of liraglutide in mice. J. Clin. Invest. 134, e178239 (2024).","DOI":"10.1172\/JCI178239"},{"key":"131_CR31","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1016\/j.cmet.2025.10.014","volume":"37","author":"J Huang","year":"2025","unstructured":"Huang, J. et al. Body-wide multi-omic counteraction of aging with GLP-1R agonism. Cell Metab. 37, 2362\u20132380.e8 (2025).","journal-title":"Cell Metab."},{"key":"131_CR32","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adk4908","volume":"16","author":"J Polex-Wolf","year":"2024","unstructured":"Polex-Wolf, J. et al. coexpressing neurons modulate the suppression of food intake and body weight by a GLP-1\/leptin dual agonist. Sci. Transl. Med. 16, eadk4908 (2024).","journal-title":"Sci. Transl. Med."},{"key":"131_CR33","doi-asserted-by":"publisher","unstructured":"Mazzaferro, S. et al. GLP-1R agonists activate human hypothalamic neurons. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2024.04.02.587825 (2026).","DOI":"10.1101\/2024.04.02.587825"},{"key":"131_CR34","doi-asserted-by":"publisher","first-page":"372","DOI":"10.2337\/db16-1102","volume":"66","author":"MA Burmeister","year":"2017","unstructured":"Burmeister, M. A. et al. The hypothalamic glucagon-like peptide 1 receptor is sufficient but not necessary for the regulation of energy balance and glucose homeostasis in mice. Diabetes 66, 372\u2013384 (2017).","journal-title":"Diabetes"},{"key":"131_CR35","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1126\/science.adj2537","volume":"385","author":"KS Kim","year":"2024","unstructured":"Kim, K. S. et al. GLP-1 increases preingestive satiation via hypothalamic circuits in mice and humans. Science 385, 438\u2013446 (2024).","journal-title":"Science"},{"key":"131_CR36","doi-asserted-by":"crossref","unstructured":"Psilopanagioti, A. et al. Glucagon-like peptide-1 receptor in the human hypothalamus is associated with body mass index and colocalizes with the anorexigenic neuropeptide nucleobindin-2\/Nesfatin-1. Int. J. Mol. Sci. 23, 14899 (2022).","DOI":"10.3390\/ijms232314899"},{"key":"131_CR37","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1038\/mp.2017.187","volume":"23","author":"L L\u00f3pez-Ferreras","year":"2017","unstructured":"L\u00f3pez-Ferreras, L. et al. Lateral hypothalamic GLP-1 receptors are critical for the control of food reinforcement, ingestive behavior and body weight. Mol. Psychiatry 23, 1157\u20131168 (2017).","journal-title":"Mol. Psychiatry"},{"key":"131_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.996179","volume":"10","author":"Y Shu","year":"2022","unstructured":"Shu, Y. et al. Gastrointestinal adverse events associated with semaglutide: a pharmacovigilance study based on FDA adverse event reporting system. Front. Public Health 10, 996179 (2022).","journal-title":"Front. Public Health"},{"key":"131_CR39","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1002\/oby.70058","volume":"33","author":"H Gasoyan","year":"2025","unstructured":"Gasoyan, H. et al. Reasons for discontinuation of obesity pharmacotherapy with semaglutide or tirzepatide in clinical practice. Obesity 33, 2296\u20132303 (2025).","journal-title":"Obesity"},{"key":"131_CR40","doi-asserted-by":"crossref","unstructured":"Brufani, C. & Morviducci, L. Semaglutide in a real-world outpatient setting: discontinuation patterns and weight maintenance. Obesity Endocrinol 1, wjaf011 (2025).","DOI":"10.1093\/obendo\/wjaf011"},{"key":"131_CR41","doi-asserted-by":"publisher","first-page":"e2457349","DOI":"10.1001\/jamanetworkopen.2024.57349","volume":"8","author":"PJ Rodriguez","year":"2025","unstructured":"Rodriguez, P. J. et al. Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among US adults with overweight or obesity. JAMA Netw. Open 8, e2457349 (2025).","journal-title":"JAMA Netw. Open"},{"key":"131_CR42","doi-asserted-by":"publisher","first-page":"231","DOI":"10.2337\/dc15-0165","volume":"39","author":"MA Nauck","year":"2016","unstructured":"Nauck, M. A. et al. A phase 2, randomized, dose-finding study of the novel once-weekly human GLP-1 analog, semaglutide, compared with placebo and open-label liraglutide in patients with type 2 diabetes. Diab. Care 39, 231\u2013241 (2016).","journal-title":"Diab. Care"},{"key":"131_CR43","doi-asserted-by":"publisher","first-page":"883","DOI":"10.15252\/msb.20167144","volume":"12","author":"F Edfors","year":"2016","unstructured":"Edfors, F. et al. Gene-specific correlation of RNA and protein levels in human cells and tissues. Mol. Syst. Biol. 12, 883 (2016).","journal-title":"Mol. Syst. Biol."},{"key":"131_CR44","doi-asserted-by":"publisher","unstructured":"Website. https:\/\/doi.org\/10.64898\/2026.04.02.26350077.","DOI":"10.64898\/2026.04.02.26350077"},{"key":"131_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.patter.2021.100255","volume":"2","author":"K Murugadoss","year":"2021","unstructured":"Murugadoss, K. et al. Building a best-in-class automated de-identification tool for electronic health records through ensemble learning. Patterns 2, 100255 (2021).","journal-title":"Patterns"},{"key":"131_CR46","unstructured":"OpenAI et al. GPT-4o system card. (2024)."}],"container-title":["npj Metabolic Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44324-026-00131-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44324-026-00131-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44324-026-00131-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T07:10:41Z","timestamp":1788246641000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44324-026-00131-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["131"],"URL":"https:\/\/doi.org\/10.1038\/s44324-026-00131-3","relation":{},"ISSN":["2948-2828"],"issn-type":[{"value":"2948-2828","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"assertion":[{"value":"17 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors are employees of nference, inc., which conducts research collaborations with various biopharmaceutical companies whose therapeutic products are included in this study. None of these companies, nor any other nference collaborator, funded, supported, or had any role in the independent study design, data acquisition, analysis, interpretation, manuscript preparation, or the decision to submit this work for publication. All analyses were conducted by the authors using de-identified electronic health record data. The authors declare no additional competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"36"}}